Investment Thesis
NIKA Pharmaceuticals exhibits terminal financial distress with zero revenue, negative stockholders equity of -$297.6K indicating technical insolvency, and only $1.9K cash reserves against $318.6K liabilities. The company's unsustainable cash burn rate of -$79.7K annually combined with severe liquidity constraints (current ratio 0.07x) indicates imminent operational failure.
Strengths
- Company maintains minimal operational footprint reducing ongoing cash burn relative to active pharmaceutical operations
- Still reporting to SEC, indicating continuation through formal restructuring processes possible
Risks
- Negative stockholders equity of -$297.6K indicates technical insolvency and high bankruptcy risk
- Severe liquidity crisis with current ratio of 0.07x and only $1.9K cash against material liabilities
- Zero revenue generation with no demonstrated product commercialization or path to profitability
- Liabilities exceed total assets by 15x, creating structural insolvency
- Unsustainable cash burn of approximately -$79.7K annually with insufficient resources for continuation
Key Metrics to Watch
- Monthly cash depletion rate and timeline to complete liquidity failure
- Any revenue generation or clinical trial advancement announcements
- Bankruptcy filing, debt restructuring, or capital raise announcements
Financial Metrics
Revenue
0.0
Net Income
-76.4K
EPS (Diluted)
$0.00
Free Cash Flow
-79.7K
Total Assets
21.0K
Cash
1.9K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-363.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.07x
Quick Ratio
0.02x
Debt/Equity
N/A
Debt/Assets
1,517.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T06:36:27.502461 |
Data as of: 2025-12-31 |
Powered by Claude AI